Modjarrad, K., Roberts, C. C., Mills, K. T., Castellano, A. R., Paolino, K., Muthumani, K., Reuschel, E. L., Robb, M. L., Racine, T., Oh, M., Lamarre, C., Zaidi, F. I., Boyer, J., Kudchodkar, S. B., Jeong, M., Darden, J. M., Park, Y. K., Scott, P. T., Remigio, C., Parikh, A. P., Wise, M. C., Patel, A., Duperret, E. K., Kim, K. Y., Choi, H., White, S., Bagarazzi, M., May, J. M., Kane, D., Lee, H., Kobinger, G., Michael, N. L., Weiner, D. B., Thomas, S. J., & Maslow, J. N. (2019). safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet infectious diseases, 19(9), 1013–1022. http://access.bl.uk/ark:/81055/vdc_100091276198.0x000034